Product Description
Epoprostenol is a synthetic analogue of the naturally occurring eicosanoid prostacyclin (prostaglandin I2 or PGI2), which is the main metabolite of arachidonic acid (Sourced from: https://err.ersjournals.com/content/26/143/160055)
Mechanisms of Action: PGI2 Agonist,PA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Canada | Chile | Colombia | Czech | Denmark | Estonia | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Luxembourg | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States
Approved Indications: Hypertension | Hypertension, Pulmonary | Hypertension | Hypertension, Pulmonary
Known Adverse Events: Dizziness | Headache | Pain Unspecified | Musculoskeletal Pain | Bradycardia | Tachycardia | Hypotension | Abdominal Pain | Chest Pain | Chronic Pain | Dyspnea | Diarrhea | Flushing
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Hypertension, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CR109201 | P1 |
Completed |
Hypertension, Pulmonary |
2023-12-05 |
21% |